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Abstract: Remarkable advances in the treatment of human immunodeficiency virus (HIV) 
disease have been blunted by widespread suboptimal adherence (ie, nonadherence), which 
has emerged as a major barrier to achieving the primary goal of antiretroviral (ARV) therapy: 
  suppression of HIV viral load. Nonsuppressed HIV viral load is associated with drug resistance, 
increased morbidity and mortality, and a higher risk of person-to-person HIV transmission. For 
HIV-infected individuals who are failing HIV treatment due to nonadherence, becoming adher-
ent is a life-saving behavior change. However, overcoming nonadherence is one of the most 
daunting challenges in the successful management of HIV disease. The purpose of this paper 
is to provide clinicians with a better understanding of nonadherence to ARV treatment and to 
review the various factors that have been associated with either adherence or nonadherence. 
Strategies are presented that may help the nonadherent individual become ready to take HIV 
medications as prescribed.
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Introduction
Human immunodeficiency virus (HIV) disease is one of the most important global 
health problems.1 Untreated HIV infection causes progressive deterioration of the 
immune system (ie, AIDS), which results in substantial morbidity and mortality. 
  Efficacious antiretroviral (ARV) treatment has transformed HIV, once considered 
invariably fatal, into a chronic manageable disease; however, nonadherence has 
emerged as a major barrier to successful treatment of this disease.
The positive impact of ARV therapy, in developed countries, has been striking. The 
median life expectancy for a 25-year old newly HIV-infected individual who has access to 
ARV treatment is an additional 39 years.2 Large observational cohort   studies have shown 
that starting ARV sooner in the course of HIV disease is associated with a significant 
reduction in mortality.3 Furthermore, ARV therapy also decreases complications from 
HIV-associated inflammation and significantly reduces the risk for transmission of HIV 
in serodiscordant couples.4 ARV treatment has become so effective that a strategy to use 
universal HIV testing and early initiation of ARV therapy as a method of eradicating the 
disease has been proposed.5 These overwhelming benefits of ARV therapy, coupled with 
its cost-effectiveness, led to the December 1, 2009, Department of Health and Human 
Services (DHHS) recommendation to start ARV treatment earlier in the course of HIV 
disease.6 Thus the number of individuals who are prescribed ARV therapy has increased, HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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and strategies for enhancement of   adherence in this growing 
population require careful attention.
Numerous studies have shown that the key to HIV 
  treatment success is suppression of HIV viral load by 
ensuring that HIV-infected individuals not only have full, 
uninterrupted access to ARV medications but also take them 
consistently every day of their lives.6 Interruptions in ARV 
therapy and missing medication doses are associated with a 
high risk for nonsuppressed HIV viral load, leading to drug 
resistance and consequent treatment failure.7 Individuals 
who develop drug resistance due to suboptimal adherence 
(ie, nonadherence) to their ARV medication regimens are 
challenging to treat, require more complex and costly ARV 
medication combinations to suppress HIV viral load, are 
hospitalized significantly more frequently than their adher-
ent counterparts,8 and experience extremely poor health 
outcomes and low quality of life.9,10 Although new ARV 
medications are more ‘forgiving’ (ie, do not seem to require 
such strict adherence as was necessary with older ARV 
regimens),11 the ability to take ARV medications consistently 
remains the key factor in ensuring positive HIV-related health 
outcomes and improving quality of life.12
The problem of nonadherence  
to HIV treatment
While many HIV-infected individuals are able to success-
fully take their ARV medications as prescribed, over one-
third (37%) of HIV-infected persons in developed countries 
have difficulty maintaining adequate levels of adherence.13 
Although developing countries have reported lower rates of 
nonadherence, newer studies have indicated that the problem 
of nonadherence is global.14 The inability of clinicians to pre-
dict adherence among their patients has been disappointing. 
No currently available screening tools can reliably prospec-
tively identify those individuals who will be either adherent 
or nonadherent. Adherence is highest among treatment-naïve 
individuals, who are presumably more motivated and less 
“fatigued” with their medication regimens. Adherence is 
enhanced by the use of potent antiretroviral regimens with a 
low daily pill count, especially when prescribed either once 
or twice a day.15
The nonadherent subset of the HIV population has 
presented one of the most daunting challenges in the suc-
cessful long-term management of HIV disease. The etiol-
ogy of nonadherence is generally multi-faceted, as will be 
discussed below. Nonadherence promotes the development 
of drug resistance mutations and necessitates use of more 
complex ARV regimens.9 Individuals who are nonadherent 
to ARV medications experience immune system deficiency 
and develop persistent debilitating constitutional symptoms 
such as fevers, night sweats, weight loss, and diarrhea.16 
Their risk for life-threatening opportunistic infections 
increases.16 Further, untreated HIV causes an inflamma-
tory process that damages vital organ systems resulting in 
increased   morbidity.17 Finally, HIV-infected individuals with 
  nonsuppressed HIV viral load are at much higher risk for 
transmitting HIV to others.4
In addition to the negative impact of nonadherence on 
individual health, the financial burden of nonadherence is also 
substantial. As HIV-infected individuals fail ARV regimens, 
each subsequent medication regimen becomes not only more 
complex but also more costly because a greater number of 
medications are needed to suppress HIV viral load.18 The 
ARV medications currently available to treat HIV disease 
are used in a strategic order and in well-defined combinations 
to ensure efficacy.19 While first-line ARV regimens typically 
consist of one to three pills taken once daily, regimens for 
individuals with drug resistance are usually dosed twice a 
day and entail use of a much larger number of medications 
with a higher total daily pill count.6 More complicated third 
and fourth line ARV regimens often cause more side effects 
and toxicities.6 In addition, drug resistance also increases 
associated health care costs. Not only do the more compli-
cated regimens cost more but additional expensive labora-
tory tests, such as genotypes and phenotypes, are required to 
assess the degree and type of HIV drug resistance to make 
appropriate prescribing decisions about alternate efficacious 
ARV regimens.20
The science of HIV treatment 
adherence
There is a plethora of published data documenting that, for 
HIV-infected individuals who experience problems taking 
ARV medications as prescribed, becoming adherent to ARV 
therapy is a life-saving behavior change.6,21 If the cycle of 
nonadherence to ARV treatment can be broken, particu-
larly at an early stage, there are many far-reaching positive 
  implications. For a nonadherent person, the ability to become 
adherent can mean the difference between experiencing 
complex, costly health problems and poor quality of life 
as opposed to enhanced health outcomes and a productive 
life. In addition, costs to the health care system are reduced 
as described above, and the risk of HIV transmission to the 
community at large is reduced. Given the importance of HIV/AIDS - Research and Palliative Care 2011:3
Table 1 Barriers and facilitators of ARV therapy adherence15,22–38
Barriers Facilitators
• Substance abuse • Sense of self-worth
• Fear of disclosure of HIV status • Seeing/feeling positive effects of ARV therapy
• Denial of the HIV diagnosis • Strong will to live
• Speaking a different language than the health care provider • Acceptance of the HIV diagnosis
• Stigma • Understanding the need for adherence
• Depression • Making use of reminder tools such as pill organizers
• Forgetfulness • Having an ARV regimen that “fits” into one’s daily schedule
• Suspicions about ARV treatment • Once daily dosing of ARV medications
• ARV regimens that are considered to be too complicated • Presence of motivational readiness
• Perceived unpleasant side-effects from ARV medications •   Perception of a positive health care provider–patient relationship
• High number of pills in an ARV regimen • Having social support
• Sleeping through medication dosing time
• Decreased quality of life
• work and family responsibilities
• Limited access to ARV medications
Abbreviations: ARV, antiretroviral; HIV, human immunodeficiency virus.
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diligent ARV adherence for the suppression of HIV viral 
load and treatment success, a number of studies have been 
conducted to improve our understanding of the phenomenon 
of adherence and to develop strategies that enhance individual 
adherence behavior.
Barriers and facilitators to HIV  
treatment adherence
Researchers have identified multiple factors associated with 
the inability, and the ability, to take ARV medications as 
prescribed15,22–38 (ie, barriers and facilitators to adherence, 
see Table 1). Facilitators of adherence improve the ability to 
take ARVs as prescribed while barriers are associated with 
the inability to take ARVs consistently. These factors appear 
to be consistent across different populations of people living 
with HIV . Known barriers to HIV treatment adherence fall 
into several broad categories including psychosocial issues, 
economic factors, substance abuse, co-morbidities including 
psychiatric disease, low health literacy, or medication-related 
issues (ie, interference with lifestyle, side effects, or undue 
complexity). Many of these factors are modifiable, or at 
least partially modifiable, with appropriate intervention. 
Conversely, categories of facilitators of adherence include 
personal motivation, support systems, organizational 
skills, and a convenient and well-tolerated ARV medication 
  regimen. These known facilitators of adherence can be used 
to enhance adherence to ARV therapy.
HIV treatment adherence interventions
Many important HIV adherence intervention studies 
have been conducted. A variety of strategies to enhance 
  adherence have been tested in noncontrolled, controlled, 
and randomized controlled studies.39–51 Adherence has been 
measured in various ways such as self-report, electronic 
devices (ie, MEMS), pharmacy refill logs, pill counting, or 
a combination of these measures. The critically important 
biologic markers of ARV treatment efficacy, which are typi-
cally used in clinical practice, have also been used to examine 
the impact of adherence interventions in some research 
studies. However, most adherence studies have not included 
these laboratory markers (eg, HIV viral load and CD4 cell 
count) as outcome measures. Several randomized controlled 
trials have reported positive results on adherence interven-
tion (ie, an increase in the rate of adherence) on behavioral 
measures such as self-report or pill counts.   However, results 
with regard to intervention impact on HIV viral load sup-
pression and increase in CD4 cell count have been less 
encouraging. Successful strategies to enhance adherence 
have included cognitive and behavioral strategies, directly 
observed therapy (DOT), modified DOT, peer support and 
effective strategies that enhance the known facilitators of 
adherence to ARV therapy.
Despite the large amount of literature focusing on 
HIV treatment adherence, the subset of the HIV-infected 
population with known nonadherence problems has been 
underrepresented in adherence intervention research. Those 
individuals who have failed HIV treatment repeatedly, who 
are particularly challenging and expensive to manage and 
who likely have the most to gain from becoming adherent 
have often been excluded or not targeted in adherence 
research. Indeed, a meta-analysis that synthesized find-
ings of HIV adherence interventions tested in randomized HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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controlled trials (RTCs) between 1996 and 2004 reported 
stronger intervention effect when participants with known 
adherence problems were targeted.39 The exclusion of 
nonadherent individuals from HIV treatment adherence 
trials unfortunately has resulted in limited knowledge 
about effective strategies to enhance adherence for this 
vulnerable group.
Readiness for adherence
Perhaps the most important personal (ie, individual level) 
component of adherence is the role of motivational readi-
ness on an individual’s ability to adhere to HIV treatment 
as   prescribed. The 2011 DHHS Guidelines, the 2010 
International AIDS Society Guidelines, and the current 
European AIDS Society guidelines for the use of antiret-
roviral agents in HIV-1 infected adults and adolescents 
recommend that ARV therapy should be initiated only when 
an HIV-infected individual is “ready” to adhere to ARV 
medications.   Readiness occurs when an individual, of his 
or her own free will, reaches a conscious awareness that a 
particular behavior is desired and beneficial.52 Readiness 
has been identified as a critical component in a number of 
healthful behaviors such as cessation of excessive alcohol 
consumption,53 adoption of asthma treatment strategies,54 
and improvement with anger management treatment.55 
Some theorists consider change and readiness to be nearly 
the same phenomenon56 while others purport that readiness 
is a separate stage that precedes change and is necessary for 
healthful behavior modification to occur.57 The presence of 
readiness has been shown to be an important predictor of 
ARV medication adherence. Higher motivational readiness 
prior to starting ARV therapy has been associated with 
subsequent adherence.58
The literature has emphasized the importance of readi-
ness and its significant role in HIV treatment adherence 
success.59–61 Placebo practice trials have been suggested 
as a method to predict readiness for ARV adherence 
among HIV-infected substance dependent individuals.62 
However, there are currently no standardized validated 
measures of HIV treatment readiness for use in clinical 
practice. Further, the impact of an individual’s level of 
readiness on subsequent HIV treatment adherence has 
not been rigorously studied in randomized controlled 
trials. Of note is one randomized controlled trial of a 
psychoeducational intervention that aimed to improve 
psychological readiness for ARV medication adherence 
and reduce   depression.63 Participants in the intervention   
group had higher readiness scores and lower depression 
scores 4 weeks post-baseline than the control group. While 
results were encouraging, the follow-up period was short, 
long-term adherence after initiation of ARV treatment 
was not examined, and HIV viral load suppression was 
not assessed.
Enhancement of readiness for HIV 
treatment adherence
Individuals who have problems taking HIV treatment as 
prescribed may lack readiness for the rigors of taking life-
long ARV medications. Motivational readiness was first 
proposed as a necessary precursor to individual ability to 
adhere to ARV treatment in 1998.52 Several readiness and 
adherence studies have demonstrated that readiness is an 
important predictor and critical component in the initiation 
and maintenance of healthful ARV adherence behavior.51,58,63 
Moreover, clinical screening tools, such as the Index of 
Readiness scale, have been tested in small studies and have 
promise for use in the clinical setting.64
Conclusions and implications
Although there is no single strategy for enhancement of 
adherence that can be applied in every clinical setting, based 
on our clinical experience and the results of our HIV treat-
ment adherence research,27,51,52,58 we offer various approaches 
for consideration by individual clinicians:
•	 an assessment of readiness for adherence before initiating 
treatment with ARV naive patients, and again if treatment 
failure occurs and a new regimen is prescribed;
•	 identification of barriers to adherence;
•	 provide help to the nonadherent individual to facilitate 
the creation of practical strategies to overcome barriers to 
adherence (ie, avenues to build social support networks, to 
enhance the patient–provider relationship, and to provide 
consistent interaction);
•	 ask the patient to make a list of his/her barriers to adher-
ence in rank order and begin by addressing the barrier to 
adherence that the individual identifies as the “easiest” 
to overcome;
•	 use potent antiretroviral regimens in accordance with 
current treatment guidelines;
•	 when possible, utilize once-daily regimens with low pill 
counts;
•	 identify and address substance abuse issues prior to initia-
tion of ARV treatment if feasible;
•	 treat depression and other mental illnesses.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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Highly effective ARV medications are available for the 
treatment of HIV disease. Such treatment affords HIV-
infected individuals the potential for long, healthy, and 
productive lives. However, management of HIV disease 
is often difficult due to the complex psychosocial issues, 
co-morbid conditions, and socioeconomic challenges that 
impact many individuals who are infected with HIV . In our 
25 years as providers on the “front-line” we have cared for 
more HIV-infected individuals who experienced problems 
with adherence to their ARV therapy than we could have 
imagined. Our experience has been that utilization of the 
individualized strategies that we have summarized in this 
paper, together with a team approach to HIV care, has led to 
the best patient outcomes.65
Despite modest progress in the area of HIV treatment 
adherence, clearly more research is required to improve 
adherence on a much larger scale.66 Clinicians would 
  welcome a simple, yet effective, screening tool for use before 
initiating ARV therapy to help them identify patients who may 
be at-risk for suboptimal adherence. In addition, HIV treat-
ment adherence interventions that can be tailored to specific 
subgroups of individuals who are failing ARV treatment, and 
that are practical for implementation in the majority of HIV 
care settings, are urgently needed.
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